Cytokinetics Announces Five Presentations Related to Aficamten at the European Society of Cardiology Congress 2024
15 Maio 2024 - 8:30AM
Cytokinetics, Incorporated (Nasdaq: CYTK) today announced five
presentations related to aficamten at the European Society of
Cardiology Congress 2024, taking place in London, UK from August
30, 2024 – September 2, 2024.
Title: Effect of Aficamten on
Structure and Function in Patients with Obstructive Hypertrophic
Cardiomyopathy: The SEQUOIA-HCM CMR
SubstudyPresenter: Ahmad Masri, M.D., MS, Director
of the Hypertrophic Cardiomyopathy Center at Oregon Health &
Science UniversityDate: Augst 30,
2024Topic: Infiltrative Myocardial
DiseaseSession Title: Cardiac Amyloidosis:
Diagnosis and OutcomesSession Type: Moderated
ePostersSession Time: 3:00-3:50 PM
BSTLocation: Station 10
Title: Clinical Application of
Biomarkers in Obstructive Hypertrophic Cardiomyopathy: Insights
from SEQUOIA-HCMPresenter: Caroline Coats, M.D.,
Ph.D., Lead Clinician, West of Scotland Inherited Cardiac
Conditions Service, Honorary Senior Lecturer, School of
Cardiovascular and Metabolic Health, University of
GlasgowDate: September 1,
2024Topic: Hypertrophic Cardiomyopathy
Session Title: Novel Therapies for Hypertrophic
Cardiomyopathy - Recent Developments and Future
ProspectsSession Type: Advances in
ScienceSession Time: 8:15-9:45 AM
BSTPresentation Time: 8:51 AM
BSTLocation: Dublin
Title: Aficamten in Patients
with Obstructive Hypertrophic Cardiomyopathy: An Integrated Safety
AnalysisPresenter: Ahmad Masri, M.D., MS, Director
of the Hypertrophic Cardiomyopathy Center at Oregon Health &
Science UniversityDate: September 1,
2024Topic: Hypertrophic Cardiomyopathy
Session Title: Novel Therapies for Hypertrophic
Cardiomyopathy - Recent Developments and Future
ProspectsSession Type: Advances in
ScienceSession Time: 8:15-9:45 AM
BSTPresentation Time: 9:09 AM
BSTLocation: Dublin
Title: Impact of Aficamten on
Echocardiographic Cardiac Structure and Function in Adults with
Symptomatic Obstructive Hypertrophic
CardiomyopathyPresenter: Sheila Hegde, M.D.,
M.P.H., Cardiovascular Medicine Specialist, Division of
Cardiovascular Medicine, Brigham and Women’s
HospitalDate: September 2,
2024Topic: Hypertrophic Cardiomyopathy
Session Title: Cardiac Myosin Inhibitors for
Treatment of Hypertrophic Obstructive CardiomyopathySession
Type: Abstract SessionsSession Time:
12:00-1:00 PM BSTPresentation Time: 12:00 PM
BSTLocation: Science Box 3
Title: Effect of Aficamten on
Patient-Reported Health Status in Obstructive Hypertrophic
Cardiomyopathy: Results from SEQUOIA-HCMPresenter:
John A. Spertus, M.D., M.P.H., Professor, Daniel J. Lauer Missouri
Endowed Chair in Metabolic and Vascular Disease Research, Clinical
Director, University of Missouri Kansas City Healthcare Institute
for Innovations in Quality and Saint Luke’s Mid America Heart
InstituteDate: September 2,
2024Topic: Hypertrophic Cardiomyopathy
Session Title: Cardiac Myosin Inhibitors for
Treatment of Hypertrophic Obstructive CardiomyopathySession
Type: Abstract SessionsSession Time:
12:00-1:00 PM BSTPresentation Time: 12:10 PM
BSTLocation: Science Box 3
About Cytokinetics
Cytokinetics is a late-stage, specialty
cardiovascular biopharmaceutical company focused on discovering,
developing and commercializing first-in-class muscle activators and
next-in-class muscle inhibitors as potential treatments for
debilitating diseases in which cardiac muscle performance is
compromised. As a leader in muscle biology and the mechanics of
muscle performance, the company is developing small molecule drug
candidates specifically engineered to impact myocardial muscle
function and contractility. Cytokinetics is preparing for
regulatory submissions for aficamten, its next-in-class cardiac
myosin inhibitor, following positive results from SEQUOIA-HCM, the
pivotal Phase 3 clinical trial in obstructive hypertrophic
cardiomyopathy. Aficamten is also currently being evaluated in
MAPLE-HCM, a Phase 3 clinical trial of aficamten as monotherapy
compared to metoprolol as monotherapy in patients with obstructive
HCM, ACACIA-HCM, a Phase 3 clinical trial of aficamten in patients
with non-obstructive HCM, CEDAR-HCM, a clinical trial of aficamten
in a pediatric population with obstructive HCM, and FOREST-HCM, an
open-label extension clinical study of aficamten in patients with
HCM. Cytokinetics is also developing omecamtiv mecarbil, a cardiac
muscle activator, in patients with heart failure. Additionally,
Cytokinetics is developing CK-586, a cardiac myosin inhibitor with
a mechanism of action distinct from aficamten for the potential
treatment of HFpEF, and CK-136, a cardiac troponin activator for
the potential treatment HFrEF and other types of heart failure,
such as right ventricular failure resulting from impaired cardiac
contractility.
For additional information about Cytokinetics,
visit www.cytokinetics.com and follow us on X, LinkedIn, Facebook
and YouTube.
Forward-Looking Statements
This press release contains forward-looking
statements for purposes of the Private Securities Litigation Reform
Act of 1995 (the "Act"). Cytokinetics disclaims any intent or
obligation to update these forward-looking statements and claims
the protection of the Act's Safe Harbor for forward-looking
statements. Examples of such statements include, but are not
limited to, statements relating to any of our other clinical
trials, statements relating to the potential benefits of omecamtiv
mecarbil, aficamten, or any of our other drug candidates.
Cytokinetics' research and development activities; the design,
timing, results, significance and utility of preclinical and
clinical results; and the properties and potential benefits of
Cytokinetics' other drug candidates. Such statements are based on
management's current expectations, but actual results may differ
materially due to various risks and uncertainties, including, but
not limited to, potential difficulties or delays in the
development, testing, regulatory approvals for trial commencement,
progression or product sale or manufacturing, or production of
Cytokinetics' drug candidates that could slow or prevent clinical
development or product approval; Cytokinetics' drug candidates may
have adverse side effects or inadequate therapeutic efficacy; the
FDA or foreign regulatory agencies may delay or limit Cytokinetics'
ability to conduct clinical trials; Cytokinetics may be unable to
obtain or maintain patent or trade secret protection for its
intellectual property; standards of care may change, rendering
Cytokinetics' drug candidates obsolete; and competitive products or
alternative therapies may be developed by others for the treatment
of indications Cytokinetics' drug candidates and potential drug
candidates may target. For further information regarding these and
other risks related to Cytokinetics' business, investors should
consult Cytokinetics' filings with the Securities and Exchange
Commission.
CYTOKINETICS® and the CYTOKINETICS and C-shaped
logo are registered trademarks of Cytokinetics in the U.S. and
certain other countries.
Contact:Cytokinetics Diane WeiserSenior Vice
President, Corporate Affairs(415) 290-7757
Cytokinetics (NASDAQ:CYTK)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Cytokinetics (NASDAQ:CYTK)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024